Drugs / alloCART-19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04173988 | Jan 2020 → Oct 2024 | B-cell childhood acute lymphoblastic leukemia | Children's Hospital of Fudan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alloCART-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04173988 ↗ |
| Modality | Cell therapy | “AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.” NCT04173988 ↗ |
| Target | CD19 | “AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.” NCT04173988 ↗ |